BMI1, Stem Cell Factor Acting as Novel Serum-biomarker for Caucasian and African-American Prostate Cancer

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Siddique, Hifzur Rahman ^a   Parray, Aijaz ^a   Zhong, Weixiong ^b   Karnes, R Jeffery ^c   Bergstralh, Eric J ^c   Koochekpour, Shahriar ^d   Rhim, Johng S ^e   Konety, Badrinath R ^a   Saleem, Mohammad ^a,f  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^f UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BMI1 PROTEIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AFRICAN AMERICAN; AGED; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER STAGING; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; SLOT BLOT HYBRIDIZATION;

AFRICAN AMERICANS; ANIMALS; BIOPSY; CELL LINE; CELL LINE, TUMOR; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; MALE; MICE; MICE, TRANSGENIC; POLYCOMB REPRESSIVE COMPLEX 1; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS;

MUS MUSCULUS;

EID: 84872029485     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052993     Document Type: Article

References (34)

1. Siegel R, Naishadham D, Jemal A, (2012) Cancer statistics. CA Cancer J Clin 62: 10-29.
2. Bickers B, Aukim-Hastie C, (2009) New molecular biomarkers for the prognosis and management of prostate cancer-the post PSA era. Anticancer Res 29: 3289-3298.
3. Levy DA, Jones JS, (2011) Management of rising prostate-specific antigen after a negative biopsy. Curr Urol Rep 12: 197-202.
4. Meulenbeld HJ, Bleuse JP, Vinci EM, Raymond E, Vitali G, et al. (2012) Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure. BJU Int doi: 10.1111/j.1464-410X.2012.11404.x.
5. Casanova-Salas I, Rubio-Briones J, Fernández-Serra A, López-Guerrero JA, (2012) miRNAs as biomarkers in prostate cancer. Clin Transl Oncol PMID pp. 22855165.
6. Madu CO, Lu Y, (2010) Novel diagnostic biomarkers for prostate cancer. J Cancer 1: 150-177.
7. Fowler JE Jr, Bigler SA, Farabaugh PB, (2002) Prospective study of cancer detection in black and white men with normal digital rectal examination but prostate specific antigen equal or greater than 4.0 ng/mL. Cancer 94: 1661-1671.
8. Siddique HR, Saleem M, (2012) Role of BMI1, a Stem Cell Factor in Cancer Recurrence and Chemoresistance: Preclinical and Clinical Evidences. Stem Cells 30: 372-378.
9. Kang MK, Kim RH, Kim SJ, Yip FK, Shin KH, et al. (2007) Elevated BMI1 expression is associated with dysplastic cell transformation during oral carcinogenesis and is required for cancer cell replication and survival. Br J Cancer 96: 126-133.
10. Cenci T, Martini M, Montano N, D'Alessandris QG, Falchetti ML, et al. (2012) Prognostic Relevance of c-Myc and BMI1 Expression in Patients With Glioblastoma. Am J Clin Pathol 138: 390-396.
11. Campbell PM, Groehler AL, Lee KM, Ouellette MM, Khazak V, et al. (2007) K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer Res 67: 2098-2106.
12. Hayward SW, Wang Y, Cao M, Hom YK, Zhang B, et al. (2001) Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res 61: 8135-8142.
13. Theodore S, Sharp S, Zhou J, Turner T, Li H, et al. (2010) Establishment and characterization of a pair of non-malignant and malignant tumor derived cell lines from an African American prostate cancer patient. Int J Oncol 37: 1477-1482.
14. Koochekpour S, Maresh GA, Katner A, Parker-Johnson K, Lee TJ, et al. (2004) Establishment and characterization of a primary androgen-responsive African-American prostate cancer cell line, E006AA. Prostate 60: 141-152.
15. Saleem M, Adhami VM, Zhong W, Longley BJ, Lin CY, et al. (2006) A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol Biomarkers Prev 15: 217-227.
16. Siddique HR, Liao DJ, Mishra SK, Schuster T, Wang L, et al. (2012) Epicatechin-rich cocoa polyphenol inhibits Kras-activated pancreatic ductal carcinoma cell growth in vitro and in a mouse model. Int J Cancer 131: 1720-1731.
17. Siddique HR, Mishra SK, Karnes RJ, Saleem M, (2011) Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy. Clin Cancer Res 17: 5379-5391.
18. Glinsky GV, Berezovska O, Glinskii AB, (2005) Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115: 1503-1521.
19. Parray A, Siddique HR, Nanda S, Konety BR, Saleem M, (2012) Castration-resistant prostate cancer: potential targets and therapies. Biologics 6: 267-276.
20. Bigler SA, Pound CR, Zhou X, (2011) A retrospective study on pathologic features and racial disparities in prostate cancer. Prostate Cancer 2011: 239460.
21. Asbell SO, Raimane KC, Montesano AT, Zeitzer KL, Asbell MD, et al. (2000) Prostate-specific antigen and androgens in African-American and white normal subjects and prostate cancer patients. J Natl Med Assoc 92: 445-449.
22. Armstrong AJ, Eisenberger MA, Halabi S, Oudard S, Nanus DM, et al. (2012) Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate Cancer. Eur Urol 61: 549-559.
23. Sasaki T, Komiya A, Suzuki H, Shimbo M, Ueda T, et al. (2005) Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients. Eur Urol 48: 224-9.
24. Shariat SF, Semjonow A, Lilja H, Savage C, Vickers AJ, et al. (2011) Tumor markers in prostate cancer I: blood-based markers. Acta Oncol 50: 61-75.
25. Spiess PE, Pettaway CA, Vakar-Lopez, Kassouf W, Wang X, et al. (2007) Treatment outcomes of small cell carcinoma of the prostate: a single-center study. Cancer 110: 1729-1737.
26. Fradet Y, (2009) Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen. Curr Opin Urol 19: 243-246.
27. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, et al. (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411-422.
28. Smith DS, Carvalhal GF, Mager DE, Bullock AD, Catalona WJ, (1998) Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men. J Urol 160: 1734-1738.
29. Gaston KE, Kim D, Singh S, Ford OH, Mohler JL, (2003) Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. J Urol 170: 990-993.
30. Balk SP, Ko YJ, Bubley GJ, (2003) Biology of prostate-specific antigen. J Clin Oncol 21: 383-391.
31. Armstrong AJ, Garrett-Mayer E, Ou Yang YC, et al. (2007) Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 25: 3965-3970.
32. Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, et al. (2006) Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 98: 516-521.
33. Taplin ME, George DJ, Halabi S, Sanford B, Febbo PG, et al. (2005) Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. Urology 66: 386-391.
34. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, et al. (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 350: 2239-2246.